Sys Rev Pharm 2025; 16(7): 1-2
A multifaceted review journal in the field of pharmacy
E-ISSN 0976-2779 P-ISSN 0975-8453/DOI: 10.31858/0975-8453.16.7.1-6

Short Communication

AI–IoT Integration: Balancing Innovation and Compliance in Pharmaceutical Manufacturing

Reshma Kodumuru*
KBI Biopharma, Inc., Durham, NC 27704, USA

Article History: *Submitted: 29.08.2025* *Accepted: 24.09.2025* *Published: 30.09.2025*

ABSTRACT

The pharmaceutical industry is moving rapidly toward digital manufacturing, with Artificial Intelligence (AI) and the Internet of Things (IoT) becoming central to predictive monitoring, process optimization, and personalized therapies. In our recent review, we examined the technological frameworks enabling this transformation. This commentary builds on that discussion and emphasizes three priority areas: (i) robust data governance as the foundation of reliable digital manufacturing, (ii) regulatory approaches that evolve alongside adaptive technologies, and (iii) the need to reframe workforce roles in the era of digital oversight. By highlighting these dimensions, I argue that the long-term success of AI–IoT integration will be defined not only by efficiency gains but also by the sector's ability to sustain trust, transparency, and patient safety.

Keywords: Pharmaceutical manufacturing, Digital transformation, Data governance, Regulatory oversight, Workforce adaptation

***Correspondence:** Reshma Kodumuru, KBI Biopharma, Inc., Durham, NC 27704, USA, E-mail: reshmakodumuru94@gmail.com

INTRODUCTION

The integration of AI and IoT into pharmaceutical manufacturing has moved from theoretical promise to real-world implementation (Kodumuru R, *et al.*, 2025). Predictive maintenance, environmental monitoring, and automated inspection systems are already in place in leading companies (Arden NS, *et al.*, 2021; Ranebennur R, *et al.*, 2023). Yet, the pace of adoption continues to raise important questions that extend beyond the technical. In reflecting on our earlier analysis (Kodumuru R, *et al.*, 2025), I view three themes as particularly critical for the next stage of progress: Ensuring data integrity, adapting regulatory frameworks, and preparing the workforce to operate confidently in digitally enabled environments.

Data governance: From compliance obligation to strategic asset

AI and IoT systems thrive only when supported by reliable and well-curated data. Poor-quality or fragmented datasets undermine predictive algorithms and can compromise product quality. In practice, issues such as inaccurate sensor calibration or incomplete data pipelines are not uncommon (Ranebennur R, *et al.*, 2023; Patel P., 2024).

For pharmaceutical firms, this means that data integrity must evolve from a narrow compliance requirement into a strategic asset. Traditional ALCOA+ principles (attributable, legible, contemporaneous, original, accurate, plus completeness, consistency, and enduring qualities) are now being extended toward dynamic data integrity frameworks that support continuous, real-time digital operations (Kodumuru R., 2023).

Approaches worth prioritizing include:

- Harmonized calibration procedures across facilities,
- Blockchain or distributed ledger technologies to secure audit trails (Patel P., 2024),
- And standardized preprocessing methods to ensure comparability of sensor outputs.

By embedding governance frameworks at the outset, manufacturers can shift from reactive quality checks to proactive process assurance, while also satisfying regulators who increasingly scrutinize the provenance and reliability of digital data streams (Arden NS, *et al.*, 2021; Kodumuru R., 2023).

Regulatory Pathways: Toward Adaptive Oversight

Conventional regulatory systems assume static manufacturing processes that undergo validation once and remain unchanged. By contrast, AI models learn and adapt over time, while IoT networks produce continuous data streams (Kodumuru R, *et al.*, 2025; Arden NS, *et al.*, 2021). This creates a tension between regulatory expectations and technological reality.

To resolve this, I believe that regulatory practice must transition from one-off validation to adaptive oversight. Such mechanisms as regulatory sandboxes, though, structured supervision in which firms and regulatory authorities can together try out new models, provide a sensible route ahead (Bender A, *et al.*, 2021). Periodic re-validation of algorithms, combined with transparency in decision-making logic, will also be very essential.

There is a need for cross-border alignment among organizations like U.S. Food and Drug Administration, European Medicines Agency, and World Health Organization (FDA, EMA, and WHO) which will help reduce redundant work and enable global scale-up (Arden NS, *et al.*, 2021). By recognizing regulators as active technology partners, rather than simply external auditors, industry can accelerate adoption, while continually preserving public trust.

Workforce adaptation: Humans as digital stewards

Although automation alleviates human effort away from monotonous manual labor, it reformulates but does not extinguish human engagement. Operators and quality specialists are increasingly acting as interpreters, curators and guardians of the AI–IoT systems. This evolution requires data-literacy, statistical-thinking, and data-analytics education at scale (Ranebennur R, *et al.*, 2023; Patel P., 2024).

At the same time, human responsibility is crucial in order to meet ethical woes, e.g., biased algorithm outputs or weak points in connected devices (Bender A, *et al.*, 2021). Holding onto the human-in-the-loop model does not allow a handoff of blame onto black-box systems around patient safety. In this respect, the pharmaceutical workforce should be seen not as displaced but as repositioned at the center of responsible digital manufacturing.

CONCLUSION

The ongoing digitization of pharmaceutical production has operationalized benefits from minimizing turn-off times to enhancing product quality. But efficiency isn't success. The next wave of AI–IoT integration should stand up based on three principles: Data integrity to build trust, regulatory agility without hindering safe innovation, and empowered human oversight to prevent abuse.

In view of the above, if these aspects are tackled with similar stringency, the convergence of AI and IoT will gradually evolve from being a mere optimization toolbox, to framework for resilient transparent and patient-centric manufacture of pharmaceuticals.

REFERENCES

1. Kodumuru R, Sarkar S, Parepally V, Chandarana J. Artificial intelligence and internet of things integration in pharmaceutical manufacturing: A smart synergy. Pharmaceutics. 2025; 17(3): 290.
2. Arden NS, Fisher AC, Tyner K, Yu LX, Lee SL, Kopcha M. Industry 4.0 for pharmaceutical manufacturing: Preparing for the smart factories of the future. Int J Pharm. 2021; 602: 120554.
3. Ranebennur R, Thirumaleshwar S, Somareddy HK, Desai R, Sandeep DS. Development of automated quality assurance systems for pharmaceutical manufacturing: A review. J Coast Life Med. 2023; 11: 1855-1864.
4. Patel P. Impact of AI on manufacturing and quality assurance in medical device and pharmaceuticals industry. SSRN. 2024.
5. Kodumuru R, Ken X. Evolving from ALCOA+ to dynamic: A modern framework for data integrity. 2023.
6. Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: What is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. Drug Discov Today. 2021; 26(2): 511-524.